In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

MLB Opening Day 2025 is finally upon us and all eyes will be on the Los Angeles Dodgers after their World Series win in 2024. The Dodgers technically already opened their season with a sweep of ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE ® trial of ...

Credit: Shutterstock / ChiccoDodiFC. Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study (NCT05693142), which is examining its investigational gene ...

US gene therapy company Regenxbio (Nasdaq: RGNX) has reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, an ...

Interim data from the Phase 1/2 part of the trial, which is sponsored by RGX-202’s developer Regenxbio, also indicate that RGX-202 appears to be working as intended, robustly increasing the production ...

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has shared new interim data from its ongoing Phase I/II AFFINITY DUCHENNE® trial, evaluating RGX-202, an investigational gene therapy for Duchenne ...

De­spite pi­o­neer­ing RNAi drug de­vel­op­ment and get­ting four ther­a­pies ap­proved, Al­ny­lam still isn’t prof­itable.